JP2020531048A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020531048A5 JP2020531048A5 JP2020530735A JP2020530735A JP2020531048A5 JP 2020531048 A5 JP2020531048 A5 JP 2020531048A5 JP 2020530735 A JP2020530735 A JP 2020530735A JP 2020530735 A JP2020530735 A JP 2020530735A JP 2020531048 A5 JP2020531048 A5 JP 2020531048A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- hcdr3
- lcdr2
- lcdr1
- lcdr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023049983A JP7564274B2 (ja) | 2017-08-18 | 2023-03-27 | 結合剤 |
| JP2024167571A JP7825015B2 (ja) | 2017-08-18 | 2024-09-26 | 結合剤 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1713298.6 | 2017-08-18 | ||
| GBGB1713298.6A GB201713298D0 (en) | 2017-08-18 | 2017-08-18 | Binding agents |
| GBGB1802595.7A GB201802595D0 (en) | 2018-02-16 | 2018-02-16 | Binding agents |
| GB1802595.7 | 2018-02-16 | ||
| GBGB1808570.4A GB201808570D0 (en) | 2018-05-24 | 2018-05-24 | Binding agents |
| GB1808570.4 | 2018-05-24 | ||
| PCT/GB2018/052347 WO2019034895A1 (en) | 2017-08-18 | 2018-08-17 | LIAISON AGENTS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023049983A Division JP7564274B2 (ja) | 2017-08-18 | 2023-03-27 | 結合剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020531048A JP2020531048A (ja) | 2020-11-05 |
| JP2020531048A5 true JP2020531048A5 (https=) | 2021-09-30 |
| JP7256580B2 JP7256580B2 (ja) | 2023-04-12 |
Family
ID=63371721
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020530735A Active JP7256580B2 (ja) | 2017-08-18 | 2018-08-17 | 結合剤 |
| JP2023049983A Active JP7564274B2 (ja) | 2017-08-18 | 2023-03-27 | 結合剤 |
| JP2024167571A Active JP7825015B2 (ja) | 2017-08-18 | 2024-09-26 | 結合剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023049983A Active JP7564274B2 (ja) | 2017-08-18 | 2023-03-27 | 結合剤 |
| JP2024167571A Active JP7825015B2 (ja) | 2017-08-18 | 2024-09-26 | 結合剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US10683350B2 (https=) |
| EP (2) | EP3668897B1 (https=) |
| JP (3) | JP7256580B2 (https=) |
| KR (1) | KR102781208B1 (https=) |
| CN (1) | CN111212852A (https=) |
| AU (2) | AU2018316742B2 (https=) |
| BR (1) | BR112020003306A2 (https=) |
| CA (1) | CA3072998A1 (https=) |
| ES (1) | ES2983651T3 (https=) |
| IL (1) | IL272643A (https=) |
| MX (1) | MX2020001873A (https=) |
| RU (1) | RU2020109544A (https=) |
| SG (1) | SG11202001425TA (https=) |
| WO (1) | WO2019034895A1 (https=) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3668897B1 (en) | 2017-08-18 | 2024-06-05 | Centessa Pharmaceuticals (UK) Limited | Binding agents |
| GB201804860D0 (en) | 2018-03-27 | 2018-05-09 | Ultrahuman Two Ltd | CD47 Binding agents |
| GB201906685D0 (en) | 2019-05-13 | 2019-06-26 | Ultrahuman Six Ltd | Activatable protein constructs and uses thereof |
| EP3986935A4 (en) * | 2019-06-19 | 2023-08-30 | Lepu Biopharma Co., Ltd. | Anti-cd47 antibodies and uses thereof |
| CN114761041A (zh) | 2019-07-16 | 2022-07-15 | 吉利德科学公司 | Hiv疫苗及其制备和使用方法 |
| EP4034171A1 (en) * | 2019-09-23 | 2022-08-03 | Cytomx Therapeutics Inc. | Anti-cd47 antibodies, activatable anti-cd47 antibodies, and methods of use thereof |
| CN114555123B (zh) | 2019-10-18 | 2024-04-02 | 四十七公司 | 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法 |
| KR20220091576A (ko) | 2019-10-31 | 2022-06-30 | 포티 세븐, 인코포레이티드 | 혈액암의 항-cd47 및 항-cd20 기반 치료 |
| LT4081305T (lt) | 2019-12-24 | 2024-11-25 | Carna Biosciences, Inc. | Diacilglicerolio kinazę moduliuojantys junginiai |
| WO2021142269A1 (en) * | 2020-01-10 | 2021-07-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of genes associated with muscle atrophy |
| WO2021142331A1 (en) * | 2020-01-10 | 2021-07-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of genes associated with cardiac muscle disease |
| KR20260017503A (ko) | 2020-02-14 | 2026-02-05 | 길리애드 사이언시즈, 인코포레이티드 | Ccr8에 결합하는 항체 및 융합 단백질, 및 이의 용도 |
| US12091681B2 (en) | 2020-03-27 | 2024-09-17 | Mendus B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| CN116133679A (zh) | 2020-06-30 | 2023-05-16 | 门德斯有限公司 | 白血病衍生细胞在卵巢癌疫苗中的用途 |
| CN111733162A (zh) * | 2020-07-01 | 2020-10-02 | 江苏莱森生物科技研究院有限公司 | 一种经基因修饰的cd47蛋白及其单克隆抗体和应用 |
| WO2022007947A1 (zh) * | 2020-07-10 | 2022-01-13 | 信达生物制药(苏州)有限公司 | 抗cd47抗体或其抗原结合片段和dna甲基化转移酶抑制剂的组合及其用途 |
| KR102757518B1 (ko) * | 2020-12-07 | 2025-01-21 | (주)이노베이션바이오 | Cd47에 특이적인 항체 및 이의 용도 |
| US12071481B2 (en) | 2020-12-23 | 2024-08-27 | D-10 Therapeutics, Inc. | Anti-CD47 antibodies and uses thereof |
| KR20230157388A (ko) | 2021-03-12 | 2023-11-16 | 멘두스 비.브이. | 백신접종의 방법 및 cd47 차단의 용도 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| CN112794903B (zh) * | 2021-04-14 | 2021-06-25 | 广州市雷德生物科技有限公司 | 一种特异性结合IFN-γ的抗体及其应用 |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CA3222277A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| WO2023277281A1 (ko) * | 2021-06-30 | 2023-01-05 | (주)이노베이션바이오 | Cd47에 특이적인 인간화 항체 및 이를 포함하는 cd47 관련 질환의 예방 또는 치료용 약학적 조성물 |
| WO2023070353A1 (en) * | 2021-10-27 | 2023-05-04 | Adagene Pte. Ltd. | Anti-cd47 antibodies and methods of use thereof |
| US20230183216A1 (en) | 2021-10-28 | 2023-06-15 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| EP4422756A1 (en) | 2021-10-29 | 2024-09-04 | Gilead Sciences, Inc. | Cd73 compounds |
| CN118488946A (zh) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | Ikaros锌指家族降解剂及其用途 |
| EP4452415B1 (en) | 2021-12-22 | 2026-02-25 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| WO2023144423A1 (en) | 2022-01-31 | 2023-08-03 | LockBody Therapeutics Ltd | Activatable bispecific anti-cd47 and anti-pd-l1 proteins and uses thereof |
| CA3253296A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Zinc Finger Degradation Agents of the Ikaros Family and Their Uses |
| AU2023240346A1 (en) | 2022-03-24 | 2024-09-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| WO2023191117A1 (ko) * | 2022-03-28 | 2023-10-05 | (주)이노베이션바이오 | 친화도가 성숙된 cd47에 특이적인 인간화 항체 |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
| CN119677546A (zh) | 2022-07-12 | 2025-03-21 | 吉利德科学公司 | Hiv免疫原性多肽和疫苗及其用途 |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| EP4638436A1 (en) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN120882725A (zh) | 2023-04-11 | 2025-10-31 | 吉利德科学公司 | Kras调节化合物 |
| WO2024220917A1 (en) | 2023-04-21 | 2024-10-24 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250042922A1 (en) | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| AU2024297978A1 (en) | 2023-07-26 | 2026-02-05 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| AU2024337913A1 (en) | 2023-09-08 | 2026-03-26 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| US20250376484A1 (en) | 2024-05-21 | 2025-12-11 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2026039365A1 (en) | 2024-08-12 | 2026-02-19 | Gilead Sciences, Inc. | Kras modulating compounds |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4637749B2 (ja) * | 2003-11-11 | 2011-02-23 | 中外製薬株式会社 | ヒト化抗ｃｄ４７抗体 |
| DE102007001370A1 (de) * | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| CN101231382B (zh) | 2008-02-26 | 2010-09-01 | 上海激光等离子体研究所 | 用于啁啾脉冲放大的光谱调制整形装置 |
| HRP20221260T1 (hr) | 2010-05-14 | 2023-03-03 | The Board Of Trustees Of The Leland Stanford Junior University | Humanizirana i kimerna monoklonska protutijela za cd47 |
| US20140140989A1 (en) | 2012-02-06 | 2014-05-22 | Inhibrx Llc | Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof |
| KR102338833B1 (ko) * | 2012-02-06 | 2021-12-13 | 인히브릭스, 인크. | Cd47 항체 및 그 사용 방법 |
| MX2015007446A (es) * | 2012-12-12 | 2015-12-07 | Vasculox Inc | Anticuerpos terapeuticos para cd47. |
| US9221908B2 (en) * | 2012-12-12 | 2015-12-29 | Vasculox, Inc. | Therapeutic CD47 antibodies |
| CA2967379A1 (en) * | 2014-11-18 | 2016-05-26 | Janssen Pharmaceutica Nv | Cd47 antibodies, methods, and uses |
| WO2016109415A1 (en) * | 2014-12-30 | 2016-07-07 | Celgene Corporation | Anti-cd47 antibodies and uses thereof |
| US10647756B2 (en) * | 2015-05-18 | 2020-05-12 | Pfizer Inc. | Humanized antibodies |
| BR112018005322A2 (pt) * | 2015-09-18 | 2018-12-11 | Arch Oncology, Inc. | anticorpo monoclonal ou seu fragmento de ligação a antígenos, composição farmacêutica, anticorpo monoclonal ou seu fragmento de ligação a antígenos para uso, método de tratamento de lesão de isquemia-reperfusão, método de tratamento de câncer em um paciente humano, método de avaliação da expressão de cd47 em células tumorais e/ou imunes usando um anticorpo monoclonal ou seu fragmento de ligação a antígenos |
| EP3747906A1 (en) * | 2016-01-11 | 2020-12-09 | Forty Seven, Inc. | Humanized, mouse or chimeric anti-cd47 monoclonal antibodies |
| EP3668897B1 (en) | 2017-08-18 | 2024-06-05 | Centessa Pharmaceuticals (UK) Limited | Binding agents |
| GB201804860D0 (en) | 2018-03-27 | 2018-05-09 | Ultrahuman Two Ltd | CD47 Binding agents |
-
2018
- 2018-08-17 EP EP18759711.7A patent/EP3668897B1/en active Active
- 2018-08-17 CN CN201880066662.5A patent/CN111212852A/zh active Pending
- 2018-08-17 ES ES18759711T patent/ES2983651T3/es active Active
- 2018-08-17 KR KR1020207007972A patent/KR102781208B1/ko active Active
- 2018-08-17 AU AU2018316742A patent/AU2018316742B2/en active Active
- 2018-08-17 EP EP24179206.8A patent/EP4435008A2/en not_active Withdrawn
- 2018-08-17 CA CA3072998A patent/CA3072998A1/en active Pending
- 2018-08-17 WO PCT/GB2018/052347 patent/WO2019034895A1/en not_active Ceased
- 2018-08-17 SG SG11202001425TA patent/SG11202001425TA/en unknown
- 2018-08-17 RU RU2020109544A patent/RU2020109544A/ru unknown
- 2018-08-17 JP JP2020530735A patent/JP7256580B2/ja active Active
- 2018-08-17 BR BR112020003306-5A patent/BR112020003306A2/pt unknown
- 2018-08-17 MX MX2020001873A patent/MX2020001873A/es unknown
-
2019
- 2019-08-19 US US16/543,884 patent/US10683350B2/en active Active
-
2020
- 2020-02-12 IL IL272643A patent/IL272643A/en unknown
- 2020-05-19 US US16/877,938 patent/US11370840B2/en active Active
-
2022
- 2022-06-24 US US17/849,101 patent/US20220332819A1/en not_active Abandoned
-
2023
- 2023-03-27 JP JP2023049983A patent/JP7564274B2/ja active Active
-
2024
- 2024-09-23 US US18/893,023 patent/US20250109202A1/en active Pending
- 2024-09-26 JP JP2024167571A patent/JP7825015B2/ja active Active
-
2025
- 2025-06-26 AU AU2025204808A patent/AU2025204808A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020531048A5 (https=) | ||
| RU2020109544A (ru) | Связывающие агенты | |
| JP2025000787A5 (https=) | ||
| JP7583707B2 (ja) | 抗ｃｄ４７抗体及びその応用 | |
| AU2016328204B2 (en) | Novel anti-mesothelin antibody and composition comprising the same | |
| JP2021519100A5 (https=) | ||
| JP2011518546A5 (https=) | ||
| JPWO2019185717A5 (https=) | ||
| EP4541813A2 (en) | Method of preparing ph-dependent antibodies | |
| RU2018145852A (ru) | Антитело против lag-3, его антигенсвязывающий фрагмент и их фармацевтическое применение | |
| TW201718657A (zh) | Ｐｄ－ｌ１抗體、其抗原結合片段及其醫藥用途 | |
| WO2014013075A2 (en) | Antibodies to highly conserved targets | |
| JP2012530496A5 (https=) | ||
| JP2010524435A5 (https=) | ||
| JPWO2019224717A5 (https=) | ||
| JP2020522280A5 (https=) | ||
| JP2016521715A (ja) | 抗ｔｗｅａｋｒ抗体およびその使用 | |
| RU2019125975A (ru) | Связывающие агенты | |
| CA3036912A1 (en) | Antibody specifically binding to pd-1 and functional fragment thereof | |
| JP2010509931A5 (https=) | ||
| JP2020522281A5 (https=) | ||
| JP2021516537A5 (https=) | ||
| JP2020505075A5 (https=) | ||
| JPWO2022256563A5 (https=) | ||
| JP2021512652A5 (https=) |